Key result
CHIR-mediated Wnt activation drives >400-fold expansion of iPSC-derived cardiomyocytes vs. ~8-fold in controls.
Why the study?
The therapeutic potential of Wnt/β-catenin signaling to enhance proliferation in differentiated cardiomyocytes, particularly across genetically diverse disease models, remains underexplored.
Timed Wnt activation overrides genetic lesions to enable disease-agnostic proliferation in differentiated human iPSC-derived cardiomyocytes, supporting standardized regenerative strategies for heterogeneous cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Wnt activation enables scalable, genotype-independent iCM expansion in vitro; leaves open translation to in vivo or clinical regenerative applications.
The therapeutic potential of Wnt/β-catenin signaling to enhance proliferation in differentiated cardiomyocytes remains underexplored, particularly in genetically diverse disease models. Here, we systematically evaluated whether pharmacological Wnt activation overrides genetic constraints to drive expansion of induced pluripotent stem cell-derived cardiomyocytes (iCMs) from healthy donors and inherited cardiomyopathy models ( GAA -Pompe disease, RYR2 -catecholaminergic polymorphic ventricular tachycardia, and KCNQ1 -long QT syndrome type 1). Using a component-defined GiWi protocol, functionally mature iCMs were generated from a high-quality iPSC line with validated trilineage differentiation capacity. Longitudinal analysis of CHIR-induced Wnt/β-catenin activation demonstrated dose-dependent proliferative amplification, with CHIR-treated iCMs achieving >400-fold monolayer expansion by passage 4 versus ~8-fold in controls. Immunofluorescence quantification revealed significantly elevated Ki67 + /cTnT + double-positive cardiomyocytes under CHIR treatment (~20% vs. ~9% in controls at passage 3). Strikingly, proliferative responses showed genetic neutrality: healthy iCMs exhibited ~432-fold expansion compared to ~406-fold in disease models (p = 0.72), with comparable Ki67 + /cTnT + ratios by passage 4 (healthy: ~8.9%; disease: ~8.3%). These findings demonstrate that timed Wnt activation overrides genetic lesions to enable disease-agnostic proliferation in differentiated iCMs. This genetic neutrality supports standardized regenerative strategies for genetically heterogeneous cardiomyopathies and arrhythmias, addressing a critical challenge in developing personalized cardiac therapies.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied Inherited cardiomyopathies (Pompe disease, CPVT, LQTS1). Pharmacological Wnt activation (CHIR) vs. Controls was evaluated on Monolayer expansion by passage 4. Pharmacological Wnt activation using CHIR induced >400-fold monolayer expansion of iPSC-derived cardiomyocytes by passage 4 compared to ~8-fold in controls, with similar expansion across healthy and disease models.
Synapse has enriched 10 related papers. Consider them for comparative context: